维普期刊资源整合服务平台（V6.5）

37篇 您的检索式：作者名="D Dimitroulopoulos"

选中清除导出查看参考文献查看引证文献引用追踪共2页首页上一页第1页下一页末页 /2 跳转

	题名	作者	年代	出处	被引量
1	Long acting octreotide in the treatment of advanced hepatocellular cancer and overexpression of somatostatin receptors: Randomized placebo-controlled trial显示文摘AIM: To estimate if and to what extent long acting octreotide (LAR) improves survival and quality of life in patients with advanced hepatocellular carcinoma (HCC). METHODS: A total of 127 cirrhotics, stages A-B, due to chronic viral infections and with advanced HCC, were enrolled in the study. Scintigraphy with 111Indium labeled octreotide was performed in all cases. The patients with increased accumulation of radionuclear compound were randomized to receive either oral placebo only or octreotide/octreotide LAR only as follows: octreotide 0.5mg s.c. every 8 h for 6 wk, at the end of wk 4-8 octreotide LAR 20 mg i.m. and at the end of wk 12 and every 4 wk octreotide LAR 30mg i.m.. Follow-up was worked out monthly as well as the estimation of quality of life (QLQ-C30 questionnaire). Patients with negative somatostatin receptors (SSTR) detection were followed up in the same manner. RESULTS: Scintigraphy demonstrated SSTR in 61 patients. Thirty were randomized to receive only placebo and 31 only octreotide. A significantly higher survival time was observed for the octreotide group (49 ± 6 wk) as compared to the control group (28 ± 1 wk) and to the SSTR negative group (28 ± 2 wk), LR = 20.39, df = 2, P < 0.01. The octreotide group presented 68.5% lower hazard ratio [95% CI (47.4%-81.2%)]. During the f irst year, a 22%, 39% and 43% decrease in the QLQ-C30 score was observed in each group respectively.CONCLUSION: The proposed therapeutic approach has shown to improve the survival and quality of life in SSTR positive patients with advanced HCC.	D Dimitroulopoulos D Xinopoulos K Tsamakidis A Zisimopoulos E Andriotis D Panagiotakos A Fotopoulou C Chrysohoou A Bazinis D Daskalopoulou E Paraskevas	2007	World Journal of Gastroenterology2007，13，23：	18
2	The role of sandostatin LAR in treating patients with advanced hepatocellular cancer显示文摘	Dimitroulopoulos D Xinopoulos D Tsamakidis K	2002	Hepato-gastroenterology2002，49，47：	1
3	Treatment of malignant colonic obstructions with metal stents and laser显示文摘	Xinopoulos D Dimitroulopoulos D Tsamakidis K	2002	Hepatogastroenterology2002，49，44：	1
4	Large-scale expansion of CD3 + CD56 + lymphocytes ca- pable of lysing autologous tumor ceils with cytokine-rich supernatants 显示文摘	Gritzapis A D Dimitroulopoulos D Paraskevas E	2002	Cancer Immunol Immunother2002，51，8：	1
5	Large scale expansion of CD3(+)CD56(+)lymphocytes capable of lysing autologoustumor cells with cytokine rich supernatants显示文摘	Gritzapis AD Dimitroulopoulos D Paraskevas E	2002	Cancer Immunol Immunother2002，51，：	1
6	Palliative treatment of advanced esophageal cancer with metal-covered expandable stents:a cost-effectiveness and quality of life study显示文摘	Xinopoulos D Dimitroulopoulos D Tsamakidis K	2005	J BUON2005，10，4：	1
7	Large scale expansion of CD3^+ CD56^+ lymphocytes capa- ble of lysing autologous tumor cells with cytokine-rich supernatants 显示文摘	Gritzapis AD Dimitroulopoulos D Paraskevas E	2002	Cancer Immunol Immunother2002，51，8：	1
8	The role of sandostatin LAR in treating patients with advanced hepatocellular cancer显示文摘	Dimitroulopoulos D Xinopoulos D Tsamakidis K	2002	Hepatogastroenterology2002，49，47：	1
9	Large- scale expansion of CD3(+)CD56(+) lymphoeytes capable of lysing autologous tumor cells with cytokine-rich supernatants 显示文摘	Gritzapis AD Dimitroulopoulos D Paraskevas E	2002	Cancer Immunol Immunother2002，51，8：	1
10	Largescale expansion of CD3(+)CD56(+)lymphocytes capable of lysing autologuous tumor cells with cytokine-rich supematants显示文摘	Gritzapis AD Dimitroulopoulos D Paraskevas E	2002	Cancer Immunol Immunother2002，51，8：	1
11	large scale expansion of CD3^+ CD56^+ lymphocytes capable of lysing autologous tumor cells with cytokine r/oh supematants CD3^+ CD56^+ 显示文摘	Gritznpis AD Dimitroulopoulos D Paraskcvas E	2002	Cancer Immunol Immunother2002，51，8：	1
12	The role of sandostatin LAR in treating patients with advanced hepatocellular cancer显示文摘	Dimitroulopoulos D Xinopoulos D Tsamakidis K	2002	Hepatogastroenterology2002，49，47：	1
13	The role of sandostatin LAR in treating patients with advanced hepatocellular cancer显示文摘	Dimitroulopoulos D Xinopoulos D Tsamakidis K	2002	Hepatogastroenterology2002，49，47：	1
14	The role of sandostatin LAR in treating patients with advanced hepatocellular cancer显示文摘	Dimitroulopoulos D Xinopoulos D Tsamakidis K	2002	Hepatogastroenterology2002，49，：	1
15	Large-scale expansion of CD3 (+)CD56 (+)lymphocytes capable of lysing autologous tumor cells with cytokine- rich supernatants 显示文摘	Gritzapis AD Dimitroulopoulos D Paraskevas E	2002	Cancer Immunol Immunother2002，51，8：	1
16	Palliative treatment of advanced esophageal cancer with metal-covered expandable stents:A cost-effectiveness and quality of life study显示文摘	Xinopoulos D Dimitroulopoulos D Tsamakidis K		0，，04：	1
17	Large-scale expansion of CD3 ( + ) CD56 ( + ) lymphocytes capable of lysing autologous tumor cells with cytokine-rich supernatants显示文摘	Gritzapis A D Dimitroulopoulos D Paraskevas E	2002	Cancer Immunol Immunother2002，51，8：	1
18	The role of sandostatin LAR in treating patients with advanced hepatocellular cancer显示文摘	Dimitroulopoulos D Xinopoulos D Tsamakidis K et 81	2002	Hepatogastmentemlogy2002，49，：	1
19	Largescale expansion of CD3+CD56+lymphocytes capable of lysing autologous tu-mor cells with cytokine rich supematants CD3+CD56'+显示文摘	Gfitznpis AD Dimitroulopoulos D Paraskevas E	2002	Cancer Im-munol immunother2002，51，8：	1
20	Largescale expansion of CD3 CD56 lymphocytes capable of lysing autologous tumor cells with cytokine - rich supernatants 显示文摘	Gritzapis AD Dimitroulopoulos D Paraskevas E	2002	Cancer Immunol Immunother2002，51，8：	1

返回顶部每页显示：

共2页首页上一页第1页下一页末页 /2 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示